Tonmya reduced daily pain scores in Phase 3 trials of nearly 1,000 patients. Tonix ended June with $125.3 million cash, funding operations into Q3 2026. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, Morgan Stanley, and more.

Shares of Tonix Pharmaceuticals have rallied 30% over the past five sessions. Investors are anticipating a key catalyst for the company. See what Wall Street is buying with instant access to ratings on 1,000 top stocks, including Goldman Sachs, Morgan Stanley, and more. Unlock all ratings now.

Shares of Tonix Pharmaceuticals are building on recent gains. The stock is trading higher as investor focus intensifies on a key, upcoming catalyst. The next 100%+ earnings move could hit this month. See how to find it live on Wednesday →